Arantxa Gonzalez

List of Publications by Citations

155 papers	8,971 citations	52 h-index	91 g-index
169 ext. papers	10,734 ext. citations	6.8 avg, IF	5.86 L-index

#	Paper	IF	Citations
155	Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. *Circulation*, **2002**, 105, 2512-7	16.7	489
154	Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2010**, 363, 552-63	59.2	452
153	Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. *Circulation*, **2004**, 110, 1263-8	16.7	320
152	Bone marrow cells adopt the cardiomyogenic fate in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 17783-8	11.5	261
151	Prevalence of left ventricular diastolic dysfunction in a general population. *Circulation: Heart Failure* , **2009**, 2, 105-12	7.6	233
150	Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. *Circulation*, **2001**, 104, 286-91	16.7	214
149	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. *Journal of the American College of Cardiology*, **2018**, 71, 1696-1706	15.1	204
148	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. *Journal of the American College of Cardiology*, **2004**, 43, 2028-35	15.1	204
147	Myocardial fibrosis: biomedical research from bench to bedside. *European Journal of Heart Failure*, **2017**, 19, 177-191	12.3	195
146	Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. *Journal of the American College of Cardiology*, **2006**, 48, 89-96	15.1	184
145	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. *Circulation: Heart Failure*, **2013**, 6, 1239-49	7.6	183
144	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1-9	5.2	177
143	Identification of a coronary vascular progenitor cell in the human heart. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 15885-90	11.5	170
142	Notch1 regulates the fate of cardiac progenitor cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15529-34	11.5	169
141	Circulating biomarkers of collagen metabolism in cardiac diseases. *Circulation*, **2010**, 121, 1645-54	16.7	168
140	The long noncoding RNA controls cardiac fibrosis and remodeling. *Science Translational Medicine*, **2017**, 9,	17.5	167
139	Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. *Circulation Research*, **2008**, 102, 597-606	15.7	163

138	T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. *Circulation: Cardiovascular Imaging*, **2013**, 6, 415-22	3.9	158
137	Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. *Journal of the American College of Cardiology*, **2018**, 71, 860-871	15.1	152
136	Biochemical assessment of myocardial fibrosis in hypertensive heart disease. *Hypertension*, **2001**, 38, 1222-6	8.5	143
135	Formation of large coronary arteries by cardiac progenitor cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1668-73	11.5	142
134	Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. *Journal of the American College of Cardiology*, **2015**, 65, 2449-56	15.1	132
133	New targets to treat the structural remodeling of the myocardium. *Journal of the American College of Cardiology*, **2011**, 58, 1833-43	15.1	129
132	Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. *Hypertension*, **2009**, 53, 236-42	8.5	120
131	Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. *Hypertension*, **2012**, 60, 677-83	8.5	118
130	Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 209-16		116
129	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. *European Heart Journal*, **2018**, 39, 4243-4254	9.5	113
128	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. *European Heart Journal*, **2018**, 39, 699-709	9.5	112
127	Clinical aspects of hypertensive myocardial fibrosis. *Current Opinion in Cardiology*, **2001**, 16, 328-35	2.1	106
126	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. *JACC: Heart Failure*, **2015**, 3, 180-8	7.9	105
125	Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. *Journal of the American College of Cardiology*, **2007**, 50, 859-67	15.1	93
124	Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. *Journal of Molecular and Cellular Cardiology*, **2002**, 34, 1585-93	5.8	93
123	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. *Hypertension*, **2018**, 71, 280-288	8.5	90
122	Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. *Journal of the American College of Cardiology*, **2016**, 67, 251-60	15.1	90
121	Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. *Hypertension*, **2010**, 55, 1418-24	8.5	89

120	Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. *Hypertension*, **2002**, 39, 75-80	8.5	89
119	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. *Cardiovascular Research*, **2013**, 99, 111-20	9.9	83
118	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. *Cardiovascular Research*, **2003**, 59, 549-62	9.9	81
117	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). *Journal of Hypertension*, **2007**, 25, 1958-66	1.9	78
116	A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. *Cardiovascular Research*, **2009**, 81, 601-9	9.9	75
115	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β up-regulation. *Clinical Science*, **2014**, 126, 497-506	6.5	74
114	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. *Medical Clinics of North America*, **2004**, 88, 83-97	7	74
113	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. *European Journal of Heart Failure*, **2015**, 17, 764-71	12.3	73
112	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. *Biomaterials*, **2014**, 35, 143-51	15.6	68
111	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H1503-9	5.2	62
110	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. *Journal of Hypertension*, **2005**, 23, 625-32	1.9	60
109	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. *Cardiovascular Ultrasound*, **2012**, 10, 10	2.4	58
108	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. *Journal of Hypertension*, **2005**, 23, 1445-51	1.9	58
107	Myocardial Remodeling in Hypertension. *Hypertension*, **2018**, 72, 549-558	8.5	58
106	Biochemical markers of myocardial remodelling in hypertensive heart disease. *Cardiovascular Research*, **2009**, 81, 509-18	9.9	57
105	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. *Journal of Hypertension*, **2011**, 29, 17-26	1.9	55
104	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. *Journal of the American College of Cardiology*, **2019**, 73, 1795-1806	15.1	52
103	Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. *Hypertension*, **2000**, 36, 1065-71	8.5	49

102	Association between left ventricular mass and telomere length in a population study. *American Journal of Epidemiology*, **2010**, 172, 440-50	3.8	46
101	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. *Hypertension*, **2019**, 73, 602-611	8.5	44
100	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. *European Journal of Heart Failure*, **2018**, 20, 1290-1299	12.3	42
99	Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. *Hypertension*, **2007**, 50, 977-83	8.5	40
98	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. *Journal of Hypertension*, **2007**, 25, 2148-57	1.9	40
97	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. *European Journal of Heart Failure*, **2015**, 17, 385-92	12.3	39
96	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. *Basic Research in Cardiology*, **2020**, 115, 39	11.8	39
95	Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. *Hypertension*, **2014**, 63, 483-9	8.5	39
94	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. *Journal of Hypertension*, **2009**, 27, 418-24	1.9	39
93	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. *Cardiovascular Research*, **2006**, 69, 899-907	9.9	38
92	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. *Journal of Hypertension*, **2005**, 23, 2297-304	1.9	36
91	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. *Current Opinion in Nephrology and Hypertension*, **2004**, 13, 197-204	3.5	34
90	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. *Circulation: Heart Failure*, **2019**, 12, e005897	7.6	33
89	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. *Journal of the American College of Cardiology*, **2019**, 73, 1398-1410	15.1	33
88	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. *Kidney International*, **2008**, S19-23	9.9	33
87	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. *Scientific Reports*, **2017**, 7, 40696	4.9	30
86	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. *Journal of Hypertension*, **2017**, 35, 853-861	1.9	30
85	p-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2015**, 1852, 1520-30	6.9	30

84	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2019**, 1866, 1421-1432	4.9	29
83	The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. *Netherlands Heart Journal*, **2016**, 24, 259-67	2.2	28
82	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. *Hypertension*, **2019**, 73, 820-828	8.5	27
81	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. *Circulation*, **2020**, 141, 751-767	16.7	27
80	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. *European Heart Journal*, **2007**, 28, 2785-91	9.5	27
79	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. *Matrix Biology*, **2018**, 66, 110-124	11.4	25
78	Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. *FASEB Journal*, **2018**, 32, fj201701408R	0.9	24
77	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. *Cardiovascular Diabetology*, **2013**, 12, 143	8.7	24
76	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMics in AGEing (HOMAGE) randomized clinical trial. *European Heart Journal*, **2021**, 42, 684-696	9.5	23
75	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. *Journal of Hypertension*, **2016**, 34, 130-8	1.9	23
74	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. *European Journal of Heart Failure*, **2020**, 22, 1711-1723	12.3	22
73	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. *Journal of Cardiovascular Medicine*, **2014**, 15, 463-9	1.9	22
72	Apoptosis in hypertensive heart disease: a clinical approach. *Current Opinion in Cardiology*, **2006**, 21, 288-94	2.4	22
71	Omics phenotyping in heart failure: the next frontier. *European Heart Journal*, **2020**, 41, 3477-3484	9.5	21
70	Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardiaca. *Revista Espanola De Cardiologia*, **2017**, 70, 832-840	1.5	20
69	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. *Free Radical Biology and Medicine*, **2015**, 81, 1-12	7.8	20
68	Cardiotrophin-1 in hypertensive heart disease. *Endocrine*, **2012**, 42, 9-17	4	20
67	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. *Nature Reviews Cardiology*, **2021**, 18, 479-498	14.8	20

66	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. *Scientific Reports*, **2017**, 7, 16042	4.9	19
65	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. *PLoS ONE*, **2016**, 11, e0167582	3.7	19
64	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. *Journal of the American College of Cardiology*, **2020**, 75, 2204-2218	15.1	18
63	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. *Heart*, **2019**, 105, 307-314	5.1	18
62	Effects of antihypertensive agents on the left ventricle: clinical implications. *American Journal of Cardiovascular Drugs*, **2001**, 1, 263-79	4	18
61	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. *Scientific Reports*, **2017**, 7, 41865	4.9	17
60	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 76, 735-744	15.1	17
59	A Urinary Fragment of Mucin-1 Subunit Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. *Kidney International Reports*, **2017**, 2, 811-820	4.1	16
58	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients 60 Years With Heart Failure and Reduced Ejection Fraction. *American Journal of Cardiology*, **2017**, 119, 2042-2048	3	16
57	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). *European Journal of Heart Failure*, **2018**, 20, 460-470	12.3	16
56	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. *European Heart Journal*, **2011**, 32, 177-83	9.5	16
55	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. *Open Heart*, **2017**, 4, e000615	3	15
54	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. *ESC Heart Failure*, **2018**, 5, 139-148	3.7	14
53	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. *Scandinavian Cardiovascular Journal*, **2014**, 48, 299-303	2	14
52	A synthetic peptide from transforming growth factor-type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats. *Antioxidants and Redox Signaling*, **2013**, 19, 1607-18	8.4	14
51	The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes. *Medical Clinics of North America*, **2017**, 101, 43-52	7	14
50	Blockade of TGF- signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. *Oxidative Medicine and Cellular Longevity*, **2012**, 2012, 726940	6.7	14
49	A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. *Journal of the American College of Cardiology*, **2006**, 47, 2335-7	15.1	14

48	Urinary peptides in heart failure: a link to molecular pathophysiology. *European Journal of Heart Failure*, **2021**, 23, 1875-1887	12.3	14
47	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. *Cardiovascular Research*, **2017**, 113, 906-914	9.9	13
46	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. *JACC: Heart Failure* , **2021**, 9, 268-277	7.9	13
45	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 832-840	0.7	12
44	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. *Journal of Hypertension*, **2013**, 31, 587-94	1.9	12
43	New directions in the assessment and treatment of hypertensive heart disease. *Current Opinion in Nephrology and Hypertension*, **2005**, 14, 428-34	3.5	12
42	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. *Journal of Hypertension*, **1998**, 16, 863-70	1.9	12
41	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. *Journal of Hypertension*, **1997**, 15, 1159-65	1.9	11
40	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. *Clinical Research in Cardiology*, **2020**, 109, 22-33	6.1	11
39	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. *Clinical Science*, **2013**, 125, 291-300	6.5	10
38	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. *Journal of Hypertension*, **2003**, 21, 2085-92	1.9	10
37	H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts. *Clinical Epigenetics*, **2020**, 12, 106	7.7	9
36	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. *Clinical Science*, **2016**, 130, 2139-2149	6.5	8
35	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy´-´A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. *European Journal of Heart Failure*, **2021**, 23, 933-944	12.3	8
34	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. *Scientific Reports*, **2019**, 9, 2956	4.9	8
33	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
32	Involvement of cardiomyocyte survival-apoptosis balance in hypertensive cardiac remodeling. *Expert Review of Cardiovascular Therapy*, **2003**, 1, 293-307	2.5	7
31	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2021**, 23, 1806-1818	12.3	7

30	The Role of Circulating Biomarkers in Peripheral Arterial Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
29	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. *Nefrologia*, **2020**, 40, 223-236	1.5	6
28	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. *Journal of Cardiovascular Electrophysiology*, **2019**, 30, 1231-1240	2.7	5
27	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. *Current Hypertension Reviews*, **2007**, 3, 1-7	2.3	5
26	Reprint of "The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking". *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118521	4.9	5
25	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. *Revista Espanola De Cardiologia*, **2020**, 73, 248-254	1.5	4
24	Myocardial fibrosis in asymptomatic and symptomatic chronic severe´primary mitral regurgitation and relationship to tissue characterisation and left ventricular´function on cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*, **2020**, 22, 86	6.9	4
23	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. *Revista Espanola De Cardiologia (English Ed)*, **2020**, 73, 835-843	0.7	3
22	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. *Revista Espanola De Cardiologia (English Ed)*, **2020**, 73, 248-254	0.7	3
21	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. *Journal of the American Heart Association*, **2019**, 8, e010430	6	3
20	Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. *Clinical and Translational Medicine*, **2021**, 11, e267	5.7	3
19	Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. *Revista Espanola De Cardiologia (English Ed)*, **2009**, 62, 305-13	0.7	2
18	La genómica y la proteómica en la investigación de la insuficiencia cardiaca. *Revista Espanola De Cardiologia*, **2009**, 62, 305-313	1.5	2
17	Myocardial fibrosis in arterial hypertension. *European Heart Journal Supplements*, **2002**, 4, D18-D22	1.5	2
16	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. *European Journal of Heart Failure*, **2021**,	12.3	2
15	Interacción cardiorrenal y evolución de la insuficiencia cardiaca. ¿Tiene un papel la proteína de unión del factor de crecimiento de tipo insulina 2?. *Revista Espanola De Cardiologia*, **2020**, 73, 835-843	1.5	2
14	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. *Nefrologia*, **2020**, 40, 223-236	0.4	2
13	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. *American Journal of Hypertension*, **2019**, 32, 15-17	2.3	2

12	A novel treatment for heart failure targets myocardial fibrosis. *Nature Medicine*, **2021**, 27, 1343-1344	50.5	2
11	Towards the molecular diagnosis of hypertensive heart disease?. *Journal of Hypertension*, **2011**, 29, 660-2	4.9	1
10	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**,	6.4	1
9	Identification of sex-specific biomarkers predicting new-onset heart failure. *ESC Heart Failure*, **2021**, 8, 3512-3520	3.7	1
8	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. *Journal of Cardiovascular Pharmacology*, **2021**, 78, e703-e713	3.1	1
7	Renin□Angiotensin□Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease **2009**, 143-150		1
6	The □Peptide for Life□nitiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. *European Journal of Heart Failure*, **2021**, 23, 1432-1436	12.3	0
5	Avances en cardiopat□ hipertensiva. Mecanismos de remodelado implicados en la transici□ de la hipertrofia a la insuficiencia cardiaca. *Revista Espanola De Cardiologia Suplementos*, **2007**, 7, 14F-21F	0.2	
4	Angiotensin II and Myocardial Fibrosis, Clinical Implications **2006**, 193-213		
3	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System **2006**, 177-189		
2	Reply: Aortic Stenosis, Left Ventricular Remodeling, and Renin-Angiotensin System ́Blockade. *Journal of the American College of Cardiology*, **2018**, 71, 2984-2985	15.1	
1	The Myocardium in Aortic Stenosis Revisited: More Complex Than Just Myocytes and Interstitial Diffuse Fibrosis. *JACC: Cardiovascular Imaging*, **2020**, 13, 2270-2273	8.4	